Puneet S. Arora - 06 Feb 2026 Form 4 Insider Report for Skye Bioscience, Inc. (SKYE)

Reporting relationship: Chief Medical Officer
Issuer ticker: SKYE
Reported as of: 06 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Feb 2026, 20:54:17 UTC
Prior SEC filing: 26 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Kaitlyn Arsenault, as Attorney-in-Fact

Key filing fact

Puneet S. Arora filed Form 4 for Skye Bioscience, Inc. (SKYE) on 09 Feb 2026.

Key facts

This page summarizes Puneet S. Arora's Form 4 filing for Skye Bioscience, Inc. (SKYE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Feb 2026, 20:54.

Change

Previous filing in this sequence was filed on 26 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002035933 Primary reporting owner

Arora Puneet S.

Relationship: Chief Medical Officer
Address: 11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Signature: /s/ Kaitlyn Arsenault, as Attorney-in-Fact
Signature date: 09 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SKYE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +125,000
Change %
Price: $0.000000
Shares after: 125,000
Date: 06 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 125,000
Exercise price: $0.8200
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option vests in equal monthly installments over the four-year period beginning January 19, 2026.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .